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BACKGROUND: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and
apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was
examined here in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition.
METHODS: Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and
422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to
compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables.
RESULTS: Neither circulating levels of IGF-I (OR¼ 1.21, 95% CI 0.75–1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (OR¼ 1.00, 95%
CI 0.66–1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR¼ 1.22, 95% CI 0.75–1.97, P-trend 0.27),
were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with
concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR¼ 1.72, 95% CI 1.05–2.83; P-interaction¼ 0.154).
CONCLUSION: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic
cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very
low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.
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Pancreatic cancer is one of the most common causes of cancer
deaths in the western world. In Europe, 48 300 deaths in men and
46 900 deaths in women due to pancreas cancer were estimated for
2008 (Ferlay et al, 2010). So far, only few risk factors for pancreatic
cancer have been clearly identified. Smoking is the major
established lifestyle factor known to cause pancreatic cancer,
accounting for up to 25 –30% of all pancreas cancer cases
(Lowenfels and Maisonneuve, 2004). Some nutrition-related
factors have also been found to be associated with pancreas
cancer risk, including excess body weight (Berrington de Gonzalez
et al, 2003; Jiao et al, 2010), history of type-2 diabetes mellitus
(Huxley et al, 2005), elevated blood levels of glucose (Gapstur et al,
2000; Batty et al, 2004; Jee et al, 2005; Stolzenberg-Solomon et al,
2005; Stattin et al, 2007; Grote et al, 2011), and possibly, chronic
hyperinsulinemia (Stolzenberg-Solomon et al, 2005).
Insulin-like growth factors (IGFs) are multifunctional peptides
that regulate cell proliferation, differentiation, and apoptosis
(Khandwala et al, 2000). IGF-I is an important regulator of
cell growth in the postnatal period (Khandwala et al, 2000).
IGF-binding proteins (IGFBP-1 through IGFBP-6) modulate the
biological effects of IGF-I, as they determine the concentration of
biologically active, unbound IGF (Jones and Clemmons, 1995).
More than 90% of circulating IGF-I is bound to IGFBP-3, and less
than 1% circulates in free form (Grimberg and Cohen, 2000).
Binding of IGF-I to the IGF-I receptor leads to stimulation of
mitogenesis in a number of cell types, to cellular protection from
apoptosis, and to cellular transformation (Grimberg and Cohen,
2000). IGFBP-3 has growth-inhibiting properties by competitively
binding IGF-I, but it also has independent growth inhibiting
effects, for example, via induction of apoptosis (Rajah et al, 1997,
2002). IGFBP activities are, among others, regulated by IGFBP
proteases, which may cleave IGFBPs into fragments with lower
affinity to IGFs (Nunn et al, 1997).
Ohmura et al (1990) have shown that IGF-I can stimulate
pancreatic cancer cell growth in vitro, and that this effect is
mediated by the IGF-I receptor (Bergmann et al, 1995). The
analysis of pancreatic cancer tissue revealed increased IGF-I
mRNA and IGF-I receptor mRNA levels, compared with tissue of
healthy individuals (Bergmann et al, 1995). Similarly, increased
levels of IGF-I and increased IGF-I receptor expression were
observed in pancreatic cancer tissue compared with normal
pancreas tissue (Karna et al, 2002). It appears that IGF-I
stimulation and subsequent suppression of tumour suppressor
chromosome 10 (PTEN) activity enhance invasiveness and
proliferation of the pancreatic cancer cells (Ma et al, 2010).
Circulating levels of IGF-1- and IGF-binding proteins have been
found to be associated with several types of cancers, including colon
(Rinaldi et al, 2010), prostate (Roddam et al, 2008), and breast
cancer (The Endogenous Hormones and Breast Cancer Collaborative
Group, 2010). However, the number of studies conducted with
respect to pancreatic cancer is limited, as is the number of cases in
these studies. The results of the prospective studies are rather
inconsistent, however, with most studies showing no association of
circulating IGF-I or IGFBP-3 levels with pancreatic cancer risk (Lin
et al, 2004; Stolzenberg-Solomon et al, 2004; Wolpin et al, 2007;
Douglas et al, 2010). Because of the inconsistencies of previous
studies, we examined the association between IGF-I, IGFBP-3, and
pancreatic cancer in the prospective European Prospective Investi-
gation into Cancer and Nutrition (EPIC) cohort, including more
than 400 incident cases of pancreatic cancer.
MATERIAL AND METHODS
Study description
European Prospective Investigation into Cancer and Nutrition is a
prospective cohort study that includes more than 500 000 male and
female participants recruited in 23 centres in 10 European
countries between 1992 and 2000. Most centres recruited subjects
from the general population, but in Utrecht and Florence, only
women from breast cancer screening programs were recruited; the
Spanish and Italian centres include blood donors, and the French
cohort consists of members of a health insurance for state school
employees. A high proportion of participants of the Oxford cohort
are vegetarians or health-conscious volunteers. The cohorts of
France, Utrecht, Florence, and Norway include women only.
Information on lifestyle and diet was collected during baseline
examination. Diet was assessed using country-specific, validated
dietary assessment instruments (Kaaks et al, 1997; Riboli and
Kaaks, 1997). Information on smoking, alcohol consumption,
physical activity, education, occupation, and medical and repro-
ductive history was collected using questionnaires and personal
interviews. Anthropometric measurements was conducted during
the baseline examination (Haftenberger et al, 2002).
Following a standardized protocol, a blood sample of 30 ml was
collected in all participating EPIC countries. In all centres except
Oxford, blood samples were stored protected from light at 5 –101C
until further processing and aliquoting. In the Oxford centre,
blood samples were collected throughout the United Kingdom and
transported to the laboratory in Norfolk by mail at an ambient
temperature. In all centres except Denmark and Sweden,
0.5–1.5 ml aliquots of serum, plasma, red blood cells, and buffy
coat were filled into plastic straws and stored in liquid nitrogen at
1961C. In the Danish centres, 1 ml aliquots were filled into tubes
and stored in the vapour phase of liquid nitrogen containers
(1501C). In Sweden, the samples were stored at 801C.
Selection of case and control subjects
Pancreatic cancer incidence data were coded according to ICD-10,
and included all invasive exocrine pancreatic cancers that were
coded as C25 (25.0– 25.3, 25.7–25.9). Cases were those EPIC
participants who developed pancreatic cancer after their recruit-
ment into the cohort and before the end of the study period.
Individuals were excluded when diagnosed with another malignant
tumour before the diagnosis of pancreatic cancer, except for non-
melanoma skin cancer, and when no blood specimens were
available for analysis. A total of 638 incident cases of pancreatic
cancer occurred until December 2006; 578 of them were primary
exocrine pancreatic tumours. Blood specimens were available for
422 of these cases. The included 422 pancreatic cancer cases were
similar in their characteristics to the overall 578 cases with
pancreatic adenocarcinoma (data not shown). Of the 422 cases, 307
(76%) were microscopically confirmed. The remaining 24% were
diagnosed by clinical symptoms, imaging results, or physical
examination. Forty-one percent of the tumours occurred in the
head of the pancreas, followed by body (7%) and tail (5%); the rest
of the tumours were of unknown localization. One control, alive
and free of cancer at time of diagnosis of the index case, was
selected for each case using incidence density sampling, that is,
controls may include subjects who became a case later in time, and
each control may be sampled more than once. Cases and controls
were matched by study centre, sex, age at enrolment (±6 months),
date of entry in the cohort, time between blood sampling and time
of last consumption of foods and drinks (o3 h, 3 –6 h, 46 h).
Laboratory assays
Serum IGF-I and IGFBP-3 concentrations were measured in the
immunoassay laboratory at the German Cancer Research Center
(DKFZ), Heidelberg, Germany. Both peptides were analysed by
enzyme-linked immunosorbent assays purchased from Beckman
Coulter (Webster, TX, USA). Before the total IGF-I analysis, IGF-I
was separated from IGF-I-binding proteins by an acid– ethanol
extraction step. Cases and matched controls were measured in
IGF-I, IGFBP-3 and pancreatic cancer risk
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singleton within the same batch. Each analytical batch further
included three different serum quality control samples. Laboratory
staff were blinded to the case/control status of the study samples.
Intra-batch and inter-batch coefficients of variation for IGF-I and
IGFBP-3 were 12.8 and 12.9%, and 6.5 and 7.2%, respectively.
Statistical analysis
Conditional logistic regression was used to examine the associations
of IGF-I and IGFBP-3 concentrations with pancreatic cancer risk.
We also computed the molar ratio of IGF-I to IGFBP-3 (IGF-I/
IGFBP-3 ratio) as a marker of the estimated level of IGF-I
biologically available to bind to its receptor. Concentrations of
IGF-I and IGFBP-3, as well as IGF-I/IGFBP-3 ratio were categorized
into sex-specific quartiles, based on the distribution among all
controls. Crude models took into account matching criteria;
multivariate models were additionally adjusted for body mass index
(continuous), smoking history (never, former, quitting smoking less
than 10 years ago, more than 10 years ago, current, with 1–9,
10–19, or X20 cigarettes per day, missing), and history of diabetes
(self-reported or high glycated haemoglobin (HbA1c) concentration
(X6.5%)). These covariates were added in the multivariable
adjusted models, because they were associated with pancreatic
cancer, correlated with IGF-1 or IGFBP-3, or changed the logistic
b-estimate by more than 10%. Further adjustment was made for
circulating C-peptide concentration, which has been measured
previously on the same subjects (Grote et al, 2011). Further analyses
were conducted with mutual adjustments between IGF-I and
IGFBP-3 concentrations.
Sub-analyses were performed, stratified by sex, smoking status at
baseline (smoker/non-smoker), diabetes (defined by self-report or
HbA1c concentrations (X6.5%), waist circumference (o/Xmedian;
96 cm for men and 80 cm for women), length of follow-up (p/42 year
of follow-up time in cases), concentration of C-peptide (o/X median,
5.57 ng ml1), and microscopical verification of cases. Odds ratios
(OR) were estimated for quartiles of IGF-1 and IGFBP-3 concentra-
tions, as well as IGF-I/IGFBP-3 ratio. Additionally, we examined the
interaction between IGF-I and IGFBP-3 levels (both variables were
dichotomized by median concentration) in a cross-classification.
Statistical tests for heterogeneity were based on w2-statistics,
calculated as the deviations of logistic beta-coefficients observed
in each of the subgroups, relative to the overall beta-coefficient.
All analyses were conducted with SAS version 9.2 (Cary, NC, USA).
RESULTS
Of the 422 cases in this analysis, 46% were men (Table 1). Mean
age at baseline was 58 years; mean age at diagnosis was 63
years. Female cases had a higher body mass index and waist
circumference than female controls, but no difference was observed
among men. Cases were more often smokers at baseline than
controls, and they more often reported a diagnosis of diabetes at
baseline or had elevated baseline blood levels of HbA1c. IGF-1 was
not statistically significantly correlated with body mass index
(Pearson’s partial correlation coefficient; adjusted for age, sex, and
study centre; r¼0.07 (95% confidence intervals (CI) 0.17 to
0.03)), waist circumference (r¼0.03 (95% CI 0.13 to 0.08)), or
circulating C-peptide level (r¼ 0.10 (95% CI 0.005 to 0.20)), and
rather weakly with height (r¼ 0.11 (95% CI 0.01 0.21)), whereas
IGFBP-3 showed correlations with body mass index (r¼ 0.12 (95%
CI 0.01 to 0.22)), waist circumference (r¼ 0.13 (95% CI 0.03 0.23)),
and C-peptide levels (r¼ 0.20 (95% CI 0.10 0.30)), but not with
height (r¼ 0.01 (95% CI 0.09 to 0.12)). IGF-1 correlated
highly and significantly with IGFBP-3 (r¼ 0.52 (95% CI 0.44
0.59)) and the molar IGF-1/IGFBP-3 ratio (r¼ 0.78 (95% CI 0.74
0.82)), whereas the ratio showed no correlation with IGFBP-3
(r¼0.09 (95% CI 0.19 to 0.01)).
Circulating levels of IGF-I or IGFBP-3 were not related to the
risk of pancreatic cancer (Table 2). Using molar IGF-I/IGFBP-3
ratio as an indicator of free IGF-I concentration, we also observed
no association with pancreatic cancer risk. The results were only
slightly affected by different types of adjustment. Additional
mutual adjustment of IGF-I and IGFBP-3 also did not strongly
change the observed associations with pancreatic cancer. There
were also no associations of IGF-I, IGFBP-3, or the ratio of these
two with pancreatic cancer, when using only microscopically
confirmed cases (Table 3).
In sub-analyses, we examined whether the association of IGF-I,
IGFBP-3, or IGF-I/IGFBP-3 with pancreatic cancer was modified
Table 1 Baseline characteristics of pancreatic cancer cases and matched
controls
Variable
Cases
(n¼422)
Controls
(n¼422)
Male subjects, n (%) 195 (46) 195 (46)
Age at recruitment (y), mean (range) 58 (30–76) 58 (30–76)
Age at diagnosis (y), mean (range) 63 (37–82) —
Follow-up (y), mean (range) 5.4 (0–13)
BMI (kg m2), mean±s.d.
Male 26.88±3.6 26.7±3.7
Female 26.5±4.9 25.2±4.2
Height (cm), mean±s.d.
Male 174.6±7.4 175.1±7.7
Female 162.3±6.6 161.5±7.2
Waist circumference (cm), mean±s.d.
Male 96.2±10.1 96.6±10.3
Female 84.3±12.3 81.1±10.6
Smoking status, n (%)a
Never 155 (37) 189 (45)
Former 130 (31) 137 (32)
Current 132 (31) 91 (22)
Education, n (%)a
Primary school or less 165 (40) 158 (39)
University 82 (20) 86 (21)
Physical activity, n (%)a
Active 62 (16) 60 (16)
Inactive 103 (27) 119 (31)
Alcohol intake at recruitment (g per day), mean±s.d.
Male 19.7±24.4 20.4±26.2
Female 9.1±13.1 7.4±10.6
Fasting status, n (%)
Fasting (X6 h) 117 (28) 113 (27)
In between (3–6 h) 158 (37) 163 (39)
Non-fasting (o3 h) 66 (16) 66 (15)
Unknown 81 (19) 80 (19)
Self-reported diabetes at recruitment, n (%) 30 (7) 17 (4)
Subjects HbA1c X6.5%, n (%) 50 (12) 28 (7)
C-peptide (ngml1), mean±s.d. 6.98±4.6 6.66±4.5
IGF-1 (ngml1), mean±s.d. 184.8±71.3 182.5±68.5
Male 187.1±74.1 185.7±68.3
Female 182.9±68.9 179.7±68.7
IGFBP-3 (ngml1), mean±s.d. 4668±1209 4665±1085
Male 4411±1267 4484±1042
Female 4890±1114 4821±1100
IGF-1/IGFBP-3 ratio 0.19±0.06 0.18±0.06
Abbreviations: BMI¼ body mass index; IGF¼ insulin-like growth factor; IGFBP¼ IGF-
binding protein; IQR¼ interquartile range; y¼ years. aPercentages do not add up to
100%, because not all subgroups are shown.
IGF-I, IGFBP-3 and pancreatic cancer risk
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by sex, smoking status, length of follow-up, waist circumference,
diabetes status, or circulating C-peptide concentration (Table 3).
With few exceptions, we did not observe statistically significant
heterogeneity between subgroups. Waist circumference modified
the association of IGF-1 and IGF-1/IGFBP-3 ratio with pancreatic
cancer risk, such that IGF-1 concentration were positively
associated with pancreatic cancer in subjects with low waist
circumference when comparing quartile 3 with quartile 1; no
association was observed when comparing the top vs the bottom
quartile. There were no statistically significant associations among
individuals with waist circumference above the median.
We cross-classified the IGF-I and IGFBP-3 concentration and
observed an increased risk of pancreatic cancer among those with
IGF-I concentration above the median and IGFBP-3 concentration
below the median (OR¼ 1.72, 95% CI 1.05–2.83); however, the test
for interaction was not statistically significant (P¼ 0.154; Table 4).
DISCUSSION
We examined the association of components of the IGF axis in
association with the risk of pancreatic cancer in the largest
prospective study, so far without finding any indication for an
association with the circulating levels of IGF-I and IGFBP-3. There
was, however, an increased risk among those with high IGF-I and
concurrently low IGFBP-3 concentrations, although the interaction
was not statistically significant. Evans et al (1997) found no
elevated serum levels of IGF-I and IGFBP-3 in pancreatic cancer
compared with controls. In contrast, Karna et al (2002) showed
significant increases in serum IGF-I and IGFBP-3 levels in patients
with pancreatic cancer compared with control subjects. Among
prospective studies, a case–control study nested within the ATBC
trial did not observe associations of serum concentrations of
IGF-1, IGFBP-3, or IGF-1/IGFBP-3 ratio with the risk of pancreatic
cancer (Stolzenberg-Solomon et al, 2004); however, this result is
based on a cohort of male smokers only. This null association,
though, is similar to the results seen in the four US cohorts that
were analysed together (Wolpin et al, 2007). Only a nested case–
control study conducted in Japan reported that individuals in the
highest quartile of IGF-I concentration had an OR of 2.31 (95% CI
0.70– 2.64) compared with participants in the lowest quartile (Lin
et al, 2004). A recently published study nested in the PLCO cohort
observed an increased risk of pancreatic cancer with increasing
IGF-I/IGFBP-3 molar ratio, which was interpreted as an indicator
of the concentration of free IGF-I (Douglas et al, 2010). We did not
observe an increase in risk with increasing IGF-I/IGFBP-3 molar
ratio, but did observe that those participants with high IGF-I levels
above the median and low IGFBP-3 concentrations had an
increased risk of pancreatic cancer.
IGFBP-3 is supposed to have growth-inhibiting properties and
one would, thus, expect that high IGFBP-3 concentrations are
inversely associated with cancer risk. On the other hand, IGFBP-3
and IGF-I are highly correlated in our cohort. In the Japanese
nested case–control study, IGFBP-3 concentration was positively
associated with pancreatic cancer risk; the risk of death from
pancreatic cancer was increased with increasing levels of serum
IGFBP-3, with the OR for the highest quartile being 2.53 (95%
CI¼ 0.93–6.85; Lin et al, 2004). However, the results of previous
studies on different types of cancer have been inconsistent with
some studies indeed showing inverse associations, but some also
showing no or even a positive association (Renehan et al, 2004).
Cleavage of IGFBPs by proteases results in IGFBP fragments with
lower affinity to IGFs and additionally influences IGF-I bioavail-
ability by reducing the amount of functional IGFBPs. It has been
Table 2 Relative risk (OR (95% CI)) of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio in EPIC
Quartilesa
OR
1 2 3 4 P-trendb Continuous P-trendc
IGF-1 men (ng ml1) 33–138 139–176 177–226 227–437 — Per 10 ngml1 —
IGF-1 women (ng ml1) 40–128 129–168 169–220 221–433 — — —
Number ofcases/controls 103/104 88/105 115/106 114/105 — — —
Model 1d 1.0 0.88 (0.58–1.31) 1.17 (0.76–1.81) 1.21 (0.75–1.93) 0.301 1.01 (0.98–1.04) 0.499
Model 2e 1.0 0.88 (0.58–1.34) 1.21 (0.77–1.90) 1.14 (0.70–1.85) 0.475 1.01 (0.98–1.04) 0.526
Model 3f 1.0 0.88 (0.58–1.35) 1.23 (0.78–1.94) 1.15 (0.70–1.88) 0.469 1.01 (0.98–1.04) 0.460
Model 4g 1.0 0.86 (0.55–1.35) 1.21 (0.74–1.98) 1.13 (0.67–1.92) 0.542 1.01 (0.98–1.04) 0.721
Model 5h 1.0 0.89 (0.56–1.42) 1.27 (0.75–2.14) 1.21 (0.66–2.25) 0.439 1.01 (0.97–1.05) 0.597
IGFBP-3 men (ng ml1) 1625–3800 3825–4548 4550–5057 5092–9367 — Per 100 ngml1 —
IGFBP-3 women (ng ml1) 1698–4085 4087–4740 4745–5321 5342–11 128 — — —
Number of cases/controls 114/104 107/106 84/106 116/105 — — —
Model 1d 1.0 0.90 (0.60–1.36) 0.72 (0.48–1.08) 1.00 (0.66–1.51) 0.789 1.00 (0.99–1.01) 0.954
Model 2e 1.0 1.00 (0.65–1.52) 0.75 (0.49–1.14) 1.13 (0.73–1.74) 0.812 1.00 (0.99–1.02) 0.593
Model 3f 1.0 1.04 (0.67–1.59) 0.76 (0.49–1.17) 1.06 (0.68–1.65) 0.941 1.00 (0.99–1.01) 0.970
Model 4g 1.0 1.05 (0.67–1.65) 0.81 (0.52–1.27) 1.07 (0.67–1.71) 0.969 1.00 (0.99–1.02) 0.696
Model 5i 1.0 1.00 (0.63–1.59) 0.76 (0.47–1.23) 0.94 (0.55–1.61) 0.673 1.00 (0.98–1.02) 0.875
IGF-I/IGFBP-3 men 0.05–0.15 0.16–0.18 0.19–0.22 0.22-0.43 — Per 0.01 —
IGF-I/IGFBP-3 women 0.05–0.12 0.13–0.16 0.17–0.21 0.22–0.44 — — —
Number of cases/controls 103/104 88/105 112/105 116/105 — — —
Model 1d 1.0 0.87 (0.57–1.33) 1.12 (0.73–1.72) 1.22 (0.75–1.97) 0.273 1.02 (0.99–1.05) 0.190
Model 2e 1.0 0.86 (0.55–1.33) 1.10 (0.70–1.70) 1.12 (0.68–1.85) 0.480 1.01 (0.98–1.04) 0.425
Model 3f 1.0 0.96 (0.61–1.52) 1.21 (0.77–1.90) 1.29 (0.77–2.16) 0.245 1.02 (0.99–1.05) 0.207
Model 4g 1.0 0.94 (0.59–1.51) 1.14 (0.71–1.84) 1.17 (0.69–2.00) 0.467 1.01 (0.98–1.04) 0.594
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; EPIC¼ European Prospective Investigation into Cancer and Nutrition; IGF¼ insulin-like growth factor;
IGFBP¼ IGF-binding protein; OR¼ odds ratio. aQuartile cut points were based on the distribution of controls. bP-trend test was based on median values of each quartile.
cP-trend test was based on continuous values. dModel 1: logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the
cohort, time between blood sampling and last consumption of foods and drinks). eModel 2: as model 1 with further adjustment for smoking (never, former, quitting smoking less
than 10 years ago, more than 10 years ago, current, with 1–9, 10–19, orX20 cigarettes per day, missing). fModel 3: as above with further adjustment for BMI (continuous) and
diabetes (defined by self-report or HbA1c concentrationX6.5%). gModel 4: as above with further adjustment for C-peptide concentration (continuous). hModel 5: as above with
further adjustment for IGFBP-3 concentration (continuous). iModel 5: as model 3 with further adjustment for IGF-I concentration (continuous).
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suggested that the maintenance of normal IGFBP levels is critical
to normal rates of cell growth and cell death (Nunn et al, 1997;
Firth and Baxter, 2002). It has also been discussed that different
assays measuring concentrations of total or intact IGFBP-3 could
cause differences between studies (Kaaks et al, 2001; Renehan et al,
2004; Rinaldi et al, 2005). We measured intact IGFBP-3, not total
IGFBP-3, which also includes IGFBP-3 fragments that are less
biologically active.
Most IGF-I in the circulation is produced by the liver (Pollak
et al, 2004). A major factor stimulating the hepatic production of
IGF-I and IGFBP-3 is growth hormone (Jones and Clemmons,
1995), but insulin also has a central role in regulating levels of
Table 3 Relative risk (OR (95% CI)) of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio for subgroups in EPIC
No
Quartilesa
Ca/Co 1 2 3 4 P-trendb P-interaction
IGF-1 men (ng ml1) 195/195 33–138 139–176 177–226 227–437 — —
IGF-1 women (ng ml1) 225/227 40–128 129–168 169–220 221–433 — —
Non-smoker 154/189 1.0 1.09 (0.57–2.07) 1.63 (0.85–3.13) 1.72 (0.91–3.28) 0.068 0.445
Smokers 261/228 1.0 0.73 (0.42–1.26) 0.98 (0.57–1.68) 0.94 (0.54–1.64) 0.878 —
Non-diabetics 349/374 1.0 0.88 (0.56–1.37) 1.23 (0.80–1.91) 1.20 (0.77–1.88) 0.244 0.545
Diabetics 54/32 1.0 1.54 (0.40–5.99) 0.69 (0.14–3.32) 0.81 (0.18–3.75) 0.629 —
Years 1 and 2 of follow-up 71/71 1.0 0.59 (0.17–2.04) 1.09 (0.29–4.09) 1.43 (0.36–5.69) 0.417 0.946
3+ years of follow-up 349/351 1.0 0.93 (0.58–1.48) 1.26 (0.77–2.08) 1.22 (0.71–2.11) 0.391 —
Male 195/195 1.0 0.71 (0.37–1.35) 1.18 (0.59–2.37) 1.09 (0.53–2.23) 0.553 0.746
Female 225/227 1.0 1.09 (0.60–1.98) 1.28 (0.68–2.42) 1.08 (0.52–2.25) 0.827 —
Low C-peptide 214/221 1.0 0.64 (0.37–1.12) 0.85 (0.48–1.51) 1.08 (0.59–1.95) 0.513 0.398
High C-peptide 206/201 1.0 1.15 (0.61–2.14) 1.57 (0.87–2.84) 1.27 (0.71–2.29) 0.396 —
Low waist circumference 205/221 1.0 0.83 (0.46–1.52) 1.80 (1.01–3.23) 1.23 (0.68–2.23) 0.246 0.040
High waist circumference 215/201 1.0 0.79 (0.44–1.41) 0.70 (0.38–1.27) 1.03 (0.56–1.86) 0.812 —
Microscopically confirmed 305/307 1.0 0.95 (0.57–1.58) 1.45 (0.83–2.52) 1.10 (0.61–2.00) 0.632 —
IGFBP-3 men (ng ml1) 195/195 1625–3800 3825–4548 4550–5057 5092–9367 — —
IGFBP-3 women (ng ml1) 227/226 1698–4085 4087–4740 4745–5321 5342–11 128 — —
Non-smoker 155/189 1.0 1.00 (0.53–1.89) 0.77 (0.40–1.47) 0.94 (0.50–1.79) 0.701 0.974
Smokers 262/227 1.0 0.94 (0.55–1.59) 0.73 (0.42–1.26) 1.05 (0.62–1.77) 0.987 —
Non-diabetics 351/373 1.0 1.02 (0.67–1.55) 0.69 (0.44–1.08) 0.99 (0.64–1.52) 0.622 0.694
Diabetics 54/32 1.0 0.61 (0.13–2.82) 1.13 (0.25–5.16) 1.12 (0.27–4.61) 0.797 —
Years 1 and 2 of follow-up 71/70 1.0 1.68 (0.59–4.78) 1.36 (0.44–4.23) 1.44 (0.46–4.47) 0.612 0.724
3+ years of follow-up 351/351 1.0 0.94 (0.58–1.52) 0.69 (0.43–1.13) 1.12 (0.68–1.85) 0.855 —
Male 195/195 1.0 0.78 (0.41–1.46) 0.54 (0.28–1.04) 0.96 (0.50–1.84) 0.774 0.362
Female 227/226 1.0 1.37 (0.74–2.56) 1.03 (0.56–1.90) 1.17 (0.61–2.25) 0.915 —
Low C-peptide 215/221 1.0 0.78 (0.45–1.35) 0.66 (0.37–1.16) 0.64 (0.36–1.14) 0.088 0.198
High C-peptide 207/200 1.0 1.21 (0.66–2.23) 0.78 (0.42–1.45) 1.47 (0.82–2.65) 0.277 —
Low waist circumference 206/221 1.0 0.74 (0.43–1.30) 0.57 (0.32–1.02) 0.92 (0.51–1.63) 0.632 0.654
High waist circumference 216/200 1.0 1.26 (0.69–2.27) 0.91 (0.49–1.68) 1.05 (0.59–1.87) 0.825 —
Microscopically confirmed 307/306 1.0 0.98 (0.57–1.66) 0.65 (0.38–1.12) 0.94 (0.55–1.62) 0.624 —
IGF-I/IGFBP-3 men 195/195 0.05 –0.15 0.16–0.18 0.19 –0.22 0.22 –0.43 — —
IGF-I/IGFBP-3 women 225/226 0.05 –0.12 0.13–0.16 0.17 –0.21 0.22 –0.44
Non-smoker 154/189 1.0 1.08 (0.56–2.11) 1.54 (0.81–2.92) 1.83 (0.94–3.57) 0.052 0.683
Smokers 261/227 1.0 0.81 (0.47–1.39) 1.03 (0.60–1.75) 1.16 (0.67–1.99) 0.442 —
Non-diabetics 349/373 1.0 1.02 (0.65–1.59) 1.27 (0.82–1.97) 1.39 (0.89–2.17) 0.097 0.543
Diabetics 54/32 1.0 0.28 (0.06–1.29) 1.00 (0.25–4.08) 0.91 (0.18–4.59) 0.923 —
Years 1 and 2 of follow-up 71/70 1.0 1.23 (0.26–5.75) 2.05 (0.38–11.08) 0.85 (0.18–4.03) 0.761 0.513
3+ years of follow-up 349/351 1.0 1.01 (0.62–1.63) 1.20 (0.75–1.94) 1.45 (0.83–2.54) 0.163 —
Male 195/195 1.0 0.49 (0.24–0.98) 1.07 (0.55–2.08) 1.28 (0.62–2.64) 0.161 0.050
Female 225/226 1.0 1.45 (0.76–2.77) 1.31 (0.67–2.55) 1.18 (0.52–2.65) 0.856 —
Low C-peptide 214/221 1.0 0.64 (0.36–1.16) 0.91 (0.50–1.64) 1.20 (0.67–2.17) 0.254 0.423
High C-peptide 206/200 1.0 1.42 (0.78–2.60) 1.33 (0.77–2.32) 1.35 (0.75–2.45) 0.370 —
Low waist circumference 205/221 1.0 0.85 (0.46–1.56) 1.73 (0.94–3.17) 1.33 (0.73–2.39) 0.162 0.028
High waist circumference 215/200 1.0 1.01 (0.56–1.81) 0.75 (0.43–1.30) 1.35 (0.74–2.48) 0.491 —
Microscopically confirmed 305/306 1.0 1.25 (0.72–2.18) 1.52 (0.88–2.61) 1.49 (0.81–2.72) 0.195 —
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; EPIC¼ European Prospective Investigation into Cancer and Nutrition; IGF¼ insulin-like growth factor;
IGFBP¼ IGF-binding protein; OR¼ odds ratio. aLogistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort,
time between blood sampling and last consumption of foods and drinks) and adjusted for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years
ago, current, with 1–9, 10–19, orX20 cigarettes per day, missing), BMI (continuous) and diabetes (defined by self-report or HbA1c concentrationsX6.5%). bP-trend test was
based on median values of each quartile.
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IGF-I and IGFBPs. For example, insulin increases the hepatic levels
of growth hormone receptors, thereby enhancing liver synthesis of
IGF-I, and in addition, insulin increases bioactivity of IGF-I by
inhibiting the synthesis of IGFBP-1 (Lee et al, 1997; Kaaks and
Lukanova, 2001). Therefore, we stratified our analysis by circulat-
ing C-peptide concentration to evaluate whether the association
between IGF-1 and IGFBP-3, and pancreatic cancer was different in
individuals with high or low C-peptide levels. However, we
observed no statistically significant interaction, which is similar
to what Wolpin et al (2007) had observed in their analysis. We also
examined whether other factors that are either well-known risk
factors for pancreatic cancer or are associated with IGF-I
concentration modified the effect of IGF-I or IGFBP-3 on
pancreatic cancer risk. However, none of the factors examined
modified the observed association. We only observed statistically
significant interactions of waist circumference with levels of IGF-I
or IGF-I/IGFBP-3 ratio, but the associations in the respective
subgroups were not consistently statistically significant.
In the EPIC cohort, only one blood sample has been collected at
baseline. It might be that repeated measurements of IGF-I and
IGFBP-3 more accurately reflect circulating levels at different
points in time. However, single serum measurements of IGF-I and
IGFBP-3 generally have been found to be quite representative
of serum concentrations over longer time periods. In a study
within the New York University Women’s Health Study cohort,
Spearman’s rank correlations between repeat measurements in
serum samples collected over time periods of more than 1 year
were 0.87 and 0.73, respectively, for IGF-I and IGFBP-3 (Lukanova
et al, 2004). Other research groups have reported similar levels of
reproducibility for circulating IGF-I and IGFBP-3 (Goodman-
Gruen and Barrett-Connor, 1997; Chan et al, 1998).
In conclusion, our results generally do not support the hypothesis
that circulating levels of IGF-1 and IGFBP-3, or the molar IGF-I/
IGFBP-3 ratio are associated with the risk of pancreatic cancer, which
confirms the results of most previous prospective studies. However,
it is noteworthy that individuals with high circulating IGF-I and low
IGFBP-3 levels have an increased risk of pancreatic cancer, compared
with those with low IGF-I and high IGFBP-3 concentrations.
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